Genentech, Inc.

Denali Therapeutics Inc.

F. Hoffmann-la Roche Ag

Xiaocheng Chen

Mark S Dennis

Robert F Kelley

Allen J Ebens

Mary A Mathieu

Mihalis S Kariolis

Robert C Wells

Mark X Sliwkowski

Thomas Pillow

Jagath Reddy Junutula

Adam P Silverman

Gail Lewis Phillips

Ryan Jefferson Watts

James T Koerber

Joy Yu Zuchero

Lawren Wu

Mason Lu

Teemu T Junttila

Janet K Jackman

Ankita Srivastava

Liping L Sun

Henry R Maun

Saroja Ramanujan

Tracy Staton

Tangsheng Yi

Kathila Rajapaksa

Yan Wu

Wei-Ching Liang

Andrew G Polson

Steven R Leong

Bing Zheng

Isidro Hotzel

Cecilia Pui Chi Chiu

Devin Tesar

Rinkan Shukla

Mary Mathieu

Lesley Ann Kane

Rishi Rakhit

Suresh Poda

Joseph W Lewcock

Do Jin Kim

Thomas Harden Pillow

Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.

Methods of engineering transferrin receptor binding polypeptides

The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.

Anti-tryptase antibodies, compositions thereof, and uses thereof

Engineered transferrin receptor binding polypeptides

The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.

Anti-CD3 antibodies and methods of use

Provided herein are polypeptides that bind to a blood-brain barrier (BBB) receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a BBB receptor-expressing cell, e.g., for transport across the BBB. Also provided herein are transferrin receptor (TfR) constructs that comprise a monomeric TfR apical domain or one or more portions of the TfR apical domain which have been circularly permuted relative to the full-length TfR sequence.

Engineered polypeptides

The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.

Anti-CLL-1 antibodies and methods of use

In one aspect, antibodies that specifically bind to a human Tau protein are provided. In some embodiments, an anti-Tau antibody recognizes an epitope within residues 111-125 of full-length human Tau, an epitope within residues 251-270 and/or residues 346-360 of full-length human Tau, or an epitope within residues 186-205 of full-length human Tau. In some embodiments, an anti-Tau antibody specifically binds to phosphorylated human Tau, unphosphorylated human Tau, and/or multiple splice isoforms of human Tau. An anti-Tau antibody disclosed herein may also include one or two modified Fc polypeptides.

Anti-Tau antibodies and methods of use thereof

The invention provides an expression and secretion system, and methods of using the same, for the expression and secretion of one fusion protein in prokaryotic cells and a second fusion protein in eukaryotic cells. Also provided herein are nucleic acid molecules, vectors and host cells comprising such vectors and nucleic acid molecules.

Expression and secretion system

Growing community of inventors

Foster City, CA, United States of America

Xiaocheng Chen